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ABSTRACT 
 
 
 
Background: The United States is in the midst of a public health crisis of 
prescription opioid addiction, abuse and overdose. Use of narcotic medication in 
the post-surgical setting may contribute to the problem. Multimodal analgesic 
plans have the potential to decrease narcotic requirements in patients after 
surgery; however, there is little prospective data to show efficacy in Head and 
Neck (H&N) surgery patients.  
 
Methods: An IRB approved, quality improvement initiative was undertaken to 
implement a multimodal analgesic protocol for all H&N surgery patients at a 
tertiary referral center. The protocol was implemented November 2017 and post-
protocol data from January 2018 to May 2018 were compared to pre-protocol 
data from May 2017 to October 2017. Data were abstracted from the electronic 
health records as well as through pre-operative and post-operative surveys. 
Average pain scores and opioid use in Morphine Milligram Equivalents (MME) 
before and after protocol implementation were compared.   
 
Results: One-hundred-and-five post-protocol patients were compared to 167 
pre-protocol patients. The adjusted median MME in the first 24 hours after 
surgery decreased significantly from 93.7mg to 58.6mg (p=0.026) with protocol 
implementation. When averaged over the length of stay (MME/HD), there was no 
significant change between the pre and post protocol cohort (57.9mg vs 46.8mg, 
p=0.211) The average pain score immediately after surgery was 3.6 and on the 
day of discharge was 2.7; neither measure changed with protocol 
implementation.  
 
Conclusion: Our multimodal analgesia plan reduced narcotic use immediately 
after surgery but not over the course of hospitalization. There was no difference 
in average reported pain scores. This study shows that implementation of a 
multimodal narcotic-sparing analgesia plan after H&N surgery is feasible. Future 
studies will need to further refine the optimal analgesia plan, optimize pain 
regimens for various patient characteristics and assess the long-term efficacy, 
safety and cost of such regimens.  
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INTRODUCTION 
 Knowledge of opioids has been around for millennia and they have been 
used both as recreational drugs and for medicinal purposes. Morphine, the first 
synthetic opioid analgesic, was extracted from opioid in 1903 in Germany.1 In the 
19th and 20th centuries, use of opioids in medicine was restrained by recognition 
of its addictive properties. 1,2 Extensive scientific research has expanded our 
understanding of how opioid agents interact with the nervous system. However, 
no one has been able to synthesize a form that retains its analgesic properties 
without the potential side effects of respiratory depression, gastrointestinal upset 
and potential for dependence and addiction. 2 This began to change at the turn of 
the 20th century for several reasons. An influential communication to the editors 
at the New England Journal of Medicine by Dr. Porter of the Boston Collaborative 
Drug Surveillance Group reported that of “11,882 patients who received at least 
one narcotic preparation, there were only four cases of reasonably well 
documented addiction in patients who had no history of addiction.” 3 This brief 
letter was subsequently cited more than 600 times and “grossly misrepresented” 
as conclusive evidence that addiction with opioids was rare. 4 In 1998, a small 
case series of 38 patients published in Pain suggested that opioid therapy could 
be a “safe, salutary and more humane alternative” to surgery or no treatment for 
intractable non-cancer pain.5 This was followed by an influential article in the 
Lancet that argued that “politics, prejudice, [and] ignorance” have led to 
undertreatment of chronic, cancer, and acute pain. 6 Gradually, even though the 
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safety and efficacy of chronic opioid use in non-cancer pain was never 
established, clinicians began to prescribe opioid therapy for acute, episodic pain.  
 During this same period, there was a widespread push from various 
governmental, pharmaceutical, and health care agencies to assess and treat 
pain. 7,8In an editorial in the Annals of Internal Medicine, Dr Max, the President of 
the American Pain Society, wrote that physicians had failed patients because 
they were not being held accountable for inadequate pain control. 9 Shortly after, 
The U.S. Veterans Health Administration rolled out a campaign to assess and 
document patient pain as “The Fifth Vital Sign.” Similarly, the Joint Commission 
on Accreditation of Healthcare Organization (JACHO) announced that pain 
assessment needed to be standard of care. 10 As a response, physicians began 
to use prescription narcotics with more frequency. Even though most 
prescriptions were written for short-term, episodic use, pain experts began to 
notice a pattern of de facto long-term use in certain patients. In contrast to 
traditional long-term opioid therapy for chronic pain or addiction, de facto long-
term use was patient selected, had considerable variability in medication type, 
dosage and frequency, and accounted for a disproportionately high amount of 
narcotics dispensed. 11 We now understand that this subset of patients had 
become addicted to prescription narcotics.  
 Currently, the United States is in the midst of a public health crisis 
involving abuse, addiction and overdose related to opioid medication. Analgesic 
medications are the most commonly prescribed class of medications in America. 
12 Between 1999 and 2012, the sales of prescription opioids have increased by at 
	   3	  
least three fold.10 During that same time span, the Center for Disease Control 
(CDC) estimates a five-fold increase in opioid related deaths.13 The Department 
of Health and Human Services (HHS) estimates that, in 2016, 17,087 deaths 
were attributable to prescription opioid overdoses along with $504 billion in 
economic costs. 14 However, according to the 2016 National Survey on Drug Use 
and Health, the majority of the estimated 11.5 million Americans who misuse 
prescription pain medication did so to relieve physical pain. Only 12.9% reported 
misuse to “feel good or get high.” 14Thus, physicians continue to face the age-old 
dilemma of how to treat pain without putting patients at risk for addiction.  
 Surgeons, in particular, face this dilemma on a daily basis. Pain after 
surgery is nearly universally experienced and is often the element of surgery that 
gives patients the most anxiety. 15 Adequate control of acute pain in post-surgical 
patients is not only humane and ethical, but also important for early mobilization 
and rehabilitation, prevention of surgical complications and lowering the risk of 
developing chronic post-surgical pain.16,17 The exact percentage of patients who 
develop chronic post-surgical pain is not well studied. Retrospective or 
epidemiologic studies, with potential for significant recall bias, estimate the rate 
to be anywhere between 5% and 50%. 16,18-20 In reviewing nearly 80,000 surgical 
patients treated at their institution over the course of 2 years, researchers at the 
University of Pennsylvania found that 9.2% of surgical patients were still using 
opioids 3 months after surgery. 21 Another recent study found that the risk of 
chronic opioid use after surgery does not differ between minor and major surgical 
procedures. 22 Since many patients are exposed to opioid medications for the 
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first time after a surgical procedure, reducing narcotic use during this period of 
time may be important to reversing the opioid crisis at a societal level.  
 
BACKGROUND and SIGNIFICANCE 
 Pain specialists and anesthesiologists advocate the use of multimodal 
pain regimens to reduce narcotic requirements after surgery. The clinical practice 
guidelines from the American Pain Society, American Society of Regional 
Anesthesia and Pain Medicine and the American Society of Anesthesiologists 
strongly recommends multimodal analgesia, defined as “use of a variety of 
analgesic medications and techniques that target different mechanisms of action 
in the peripheral and/or central nervous system” for postoperative pain. 23 A 
systematic review of randomized controlled trials comparing acetaminophen, 
non-steroidal anti-inflammatory drugs (NSAIDs) and cyclo-oxygenase 2 (COX-2) 
inhibitors to each other or placebo in patients with a morphine patient-controlled 
analgesia (PCA) found a significant decline in 24-hour morphine use when the 
non-steroidal medications were used. 24 The benefit of adding each agent ranged 
from a decrease of 6.3mg to 10.9mg of morphine but benefit of multiple agents 
was not assessed. 24 An earlier meta-analysis found similar results reporting a 
morphine dose reduction ranging from 7.2 to 27.8mg with the addition of various 
single agents. 25 A large-scale review of patients after total hip replacement and 
knee arthroplasties looking at effect of multiple modalities of pain control found 
that addition of analgesic modes had fewer respiratory and gastrointestinal 
complications and a decrease in opioid prescriptions in a stepwise fashion. 26 
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The authors recommended the combined use of multiple modalities in 
perioperative analgesic protocols but also noted that the optimal regimen is not 
known.  
 Multimodal analgesia studies and recommendations have largely focused 
on general surgery and orthopedic procedures. 23 However, the benefits of 
multimodal pain strategies have been extrapolated to head and neck (H&N) 
procedures and recommended by the Enhanced Recovery After Surgery (ERAS) 
Society. 27 H&N surgical procedures may differ from general surgery or 
orthopedic procedures in several important respects. First, mucosal injury and 
pain may be different from soft tissue or visceral pain. Second, surgery of the 
neck often transects numerous sensory nerves and thus may also result in a 
different post-surgical pain experience. To date, few studies have assessed the 
efficacy and safety of multimodal analgesia in post-surgical H&N surgery patients 
(Appendix I). A randomized controlled trial of mucosal H&N surgery patients 
found that perioperative gabapentin (300mg twice daily) had no effect on narcotic 
usage but some benefit in terms of pain score. 28 Another recent retrospective, 
matched-control study showed that postoperative treatment with celecoxib 
decreased narcotic usage after H&N procedures requiring free tissue 
reconstruction. 29 Only one study has specifically looked at multimodal analgesia. 
Oltman et al found that at their institution, 64 of 222 (29%) of patients undergoing 
outpatient H&N surgical procedures elected multimodal analgesia. Of these 
patients, 39 were able to avoid postoperative narcotic medications. The objective 
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of this study was to see if implementation of a multimodal analgesic protocol 
would reduce narcotic usage in patients undergoing H&N surgeries.  
 
METHODS 
Patient Selection 
 A prospective continuous quality improvement (CQI) initiative with 
institutional review board (IRB) approval from the University of North Carolina – 
Chapel Hill was used to collect data between May 2017 and May 2018. All adult 
patients undergoing surgery with one of six H&N surgeons during this time period 
were included. H&N procedures included all soft tissue neck surgeries (i.e. 
thyroidectomy, parathyroidectomy, parotidectomy, neck dissection and lymph 
node excision) as well as surgeries involving the oral cavity, pharynx and larynx. 
The surgeries were not limited to the H&N region, however, as free tissue 
transfer or local flap reconstruction after oncologic ablative procedures were also 
included. Surgeries that involved tonsillectomy alone or endoscopic procedures 
such as direct laryngoscopy were excluded. Baseline data were collected 
between May 2017 and November 2017. A multimodal pain protocol was 
implemented for all H&N surgery patients on November 1st, 2017. We allowed for 
a period of two months for adjustment and for house staff and floor nurses to 
become familiar with the protocol. The medications for the protocol were 
incorporated into our pre-surgery and post-surgery electronic medical record 
(EMR) order sets. During this two-month period, we met with house staff and 
floor nurses and nurse managers to inform them of the protocol and to address 
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any concerns that arose. Post-implementation data were collected between 
January 2018 and May 2018.  
 
Multimodal Analgesia Protocol 
 In collaboration with a pain management specialist from our Department of 
Anesthesia, a multimodal analgesia plan was developed and agreed upon 
among all surgeons in the Division of Head and Neck Surgery. Given the diverse 
range of surgical procedures encompassed by this protocol, we attempted to 
stratify procedures by extent of surgery and anticipated length of stay. 
Procedures such as thyroidectomy, parathyroidectomy, parotidectomy, lymph 
node excision and neck mass excision were defined as “minor” H&N procedures. 
These procedures are shorter in duration and can either be done on an 
outpatient basis or with short inpatient hospitalizations of 1-3 days. Procedures 
such as glossectomy, partial or total pharyngectomy, mandibulectomy, total 
laryngectomy and modified or radical neck dissection were defined as “major” 
H&N procedures. These procedures, often performed in combination with one 
another, are longer in terms of operative time and are associated with longer 
hospitalizations. This division also correlated with intermediate and high levels of 
anticipated post-operative pain. 30  
 The multimodal analgesia protocol included acetaminophen (1000 mg IV 
or 650 mg PO every 4-6 hours as needed for mild pain, 4gm/24hr limit) and 
ketorolac (15 mg IV every 6 hours for 48 hours) for all patients after surgery. 
Initially, the protocol also included injection of bupivicaine at the end of surgery. 
	   8	  
However, this was abandoned due to inconsistent availability of the medication in 
our operating suites. In addition, for major H&N surgery patients, pregabalin (100 
mg PO) was given in pre-op on the day of surgery and then continued at a dose 
of 50mg PO twice daily for 10 days. As needed (PRN) opioid pain medication 
was ordered at the discretion of the provider. At our institution, this often 
consisted of oxycodone (5 mg PRN every 4-6 hours) and morphine (2-4 mg IV) 
for breakthrough pain. Major H&N surgery patients received a hydromorphone 
patient controlled analgesia (PCA) pump for the first 24-48 hours post-surgery 
before transitioning to oxycodone. The protocol did not restrict the amount of pain 
medication patients could receive, and medications could be modified or 
increased at the discretion of the clinical care team. Ketorolac was not given to 
patients with kidney disease. All medications were held when contraindicated or 
if there was concern for side effects.  
 
Data Collection 
 Study data were collected and managed using REDCap (Research 
Electronic Data Capture) electronic data capture tools at the University of North 
Carolina. 31 REDCap is a secure, web-based application designed to provide an 
interface for valid data entry, audit trails for tracking and data manipulation, 
export and import procedures. It also allows for automated and timed survey 
gathering through email. An initial survey, given to patients during their pre-
operative clinic visit, queried prior chronic pain, baseline levels of pain, baseline 
narcotic medication use and anticipated level of post-surgical pain (Appendix II). 
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A post-operative survey was administered to patients 1-2 days after surgery 
(Appendix III). This was either obtained in person if the patient was still admitted 
or via a REDCap generated email if the patient had provided an email address 
for contact in their pre-operative survey.  
 Patient’s age at time of surgery, sex, race, smoking status, past medical 
history, medication use at time of surgery, pathology from surgery and surgical 
procedures were abstracted from the EMR. Patient was also asked about chronic 
pain and baseline narcotic use on the pre-operative survey. The patient was 
designated to have chronic pain if they had a diagnosis of chronic pain on EMR 
or reported it on the pre-operative survey. Similarly, patients were considered to 
take opioid medication if it was listed on their medication list pre-operatively or if 
they reported it on the pre-operative survey. Surgical procedures were 
categorized as either “minor” or “major” in the following fashion. All procedures 
involving ablation of a mucosal malignancy (e.g. glossectomy, pharyngectomy, 
laryngectomy) were considered “major.” Similarly, all neck dissections for 
malignancy were considered “major.” All salvage procedures for persistent or 
recurrent tumor, as well as osteoradionecrosis were categorized as “major.” Soft 
tissue neck procedures (e.g. parotidectomy, parathyroidectomy, thyroidectomy, 
neck mass excision) were categorized as “minor.” 
 
Outcomes 
 The primary outcome of this study was inpatient narcotic use as measured 
by morphine milligram equivalent (MME) in the first 24 hours after surgery and 
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MME per day averaged throughout the hospitalization (MME/HD). Our secondary 
outcomes measured were average documented pain scores (scale 1-10) in the 
first 24 hours after surgery and on the day of discharge. The relationship 
between narcotic usage, pain scores and patient’s reported satisfaction with pain 
control (scale of 1-4 with 4 being extremely satisfied) was also analyzed. Patient 
reported satisfaction scores were only available for patients who completed a 
post-operative survey.  
 
Statistical Analysis 
  Descriptive statistics were used to describe patient, disease and 
treatment characteristics. Bivariate analysis for pain score was performed using 
the 2-Sample T-Test for categorical variables and Pearson’s Correlation for 
continuous variables. Bivariate analysis for MME and MME/HD was performed 
using Wilcoxon Rank-Sum test for categorical variables and Spearman’s 
Correlation for continuous variables. Pre-protocol and post-protocol narcotic use 
and pain scores were analyzed with intention-to-treat based on the date of 
surgery. Multivariate analysis assessing opioid usage and pain scores between 
the two groups was performed with adjustment for all assessed covariates. 
Statistical analysis was performed using STATATM version 15.1 (College Station, 
Texas).  
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FINDINGS 
 A total of 365 patients were initially captured in our database of patients 
treated by the division of H&N surgery department between May 2017 and May 
2018. Ninety-three patients were excluded from study analysis for the following 
reasons: 9 (9.7%) due to surgery cancellation, 37 (39.8%) due to nature of 
procedure and 47 (50.5%) because they occurred in the two months immediately 
after protocol implementation. The washout period, November and December 
2017, allowed for providers to become familiar with the protocol so that the post-
intervention results would better reflect clinical practice when protocol was 
actively utilized. Two hundred and seventy-two patients met inclusion criteria and 
were included for study analysis: 167 before protocol implementation and 105 
after protocol implementation. Two hundred and thirty-nine patients completed a 
pre-operative survey and 126 completed a post-operative survey for a survey 
response rate of 88% and 46%, respectively.  
 The characteristics of these patients are shown in Table 1. Utilization of 
various medications that comprise the multimodal analgesia regimen before and 
after protocol implementation is shown in Table 2. The cohorts of patients before 
and after protocol implementation were similar in age, sex and race distribution. 
There were more patients with benign disease in the post-implementation cohort 
(66% vs 55%) but more underwent major H&N procedures (64% vs 36%). There 
was no significant difference between the two groups in terms of mean length of 
hospitalization or complications requiring return to operating room rates.  
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 Narcotic use as measured by Morphine Milligram Equivalents (MME) in 
the first 24 hours after surgery and averaged over the course of the 
hospitalization (MME/HD) was examined for 220 patients who were hospitalized 
for more than 24 hours. One patient had an extremely complicated 
hospitalization course spanning an 86-day admission and thus was excluded 
from analysis of narcotic use. The distribution for both MME in the first 24 hours 
and MME/HD were both positively skewed. The median opioid use in the first 24 
hours was 48.0 mg (IQR 22.5-90.0) with 16 patients not receiving any opioid 
medications post-operatively. When averaged over the length of hospitalization, 
the median opioid use was 38.4 mg/day (IQR 15.0-74.0). Bivariate analysis 
showed that age, race, smoking status, history of chronic pain, pre-operative 
narcotic use, anticipated post-operative pain score and extent of surgery were 
significantly associated with opioid use in the first 24 hours after surgery (Table 
3). On multivariate analysis, age, prior narcotic use and extent of surgery 
remained significantly associated. Age, smoking status, pre-operative history of 
chronic pain, narcotic use and anticipated post-operative pain were significantly 
associated with average MME over the course of hospitalization. After 
multivariate adjustment, only age, prior narcotic use and anticipated post-
operative pain remained significant. After adjustment for all covariates, patients 
after protocol implementation had a significant decrease in opioid use in the first 
24 hours (93.7mg vs 58.6mg, p=0.026) and but not averaged over the course of 
hospitalization (57.9mg/day vs 46.8mg/day, p=0.211, Table 5).  
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 In the first 24 hours after surgery, patient’s average pain score was 3.8 
(SD 2.1). On the day of discharge, patient’s average pain score was 2.7 (SD 2.6) 
and did not depend on length of stay. Bivariate analysis showed that the average 
pain score in the first 24 hours after surgery was significantly associated with 
age, sex and patient’s preoperative anticipation of pain (Table 4). Similarly, 
bivariate analysis showed that patient’s average reported pain score on day of 
discharge was significantly associated with age, pre-operative diagnosis of 
chronic pain, prior narcotic use and post-operative anticipated pain score. After 
multivariate adjustment, only age and pre-operative anticipation of pain remained 
significantly associated with pain scores in both the first 24 hours after surgery 
and at time of discharge. Aggregate patient reported pain scores did not change 
after implementation of multimodal analgesia plan, even when adjusting for 
covariates. The adjusted average 24-hour pain score before and after protocol 
implementation were 3.6 and 3.7, respectively (p=0.780).  The adjusted average 
discharge pain score before and after protocol implementation were both 2.7 
(p=0.868) (Table 5).  
   
DISCUSSION 
 Our study, to our knowledge, is the first to study the effect of multimodal 
analgesia in Otolaryngology with an intention to treat study design. Different 
aspects of the multimodal analgesia protocol were implemented with different 
degrees of success. Post-protocol, the utilization of ketoralac in our patient 
population increased from 10% to 57%. Use of acetaminophen at our institution 
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was high at baseline (69%) and increased to 88% after the protocol. For patients 
undergoing a major H&N procedure, use of pregabalin on day of surgery 
increased from 11% to 76%. Certain medications may have been omitted due to 
contraindications, adverse reactions or simply because the ordering provider 
forgot. By comparing our outcomes pre- and post-protocol implementation, we 
wanted to assess both the feasibility of implementing such a multimodal 
analgesia plan and its effectiveness. H&N patients, especially ones undergoing 
surgical treatment for upper aerodigestive tract malignancies are often medically 
complex. Therefore, we did not expect that perfect implementation of the protocol 
would be feasible. Unfortunately, it was not possible to reliably ascertain the 
reason a specific medication was not ordered. We cannot determine what 
proportions of missed ordered medications were omitted due to patient factors 
and which were omitted by error. Nevertheless, including all post-protocol 
patients for analysis (rather than just the ones who received the medications 
according to protocol) allows us to get a better sense of the effect implementation 
of such a protocol has in actual clinical practice. 
 Our data showed a roughly one third reduction in the amount of narcotic 
pain medication used in the first 24 hours after implementation of a multimodal 
analgesic protocol. Adjustment for patient and surgical characteristics were made 
as the two cohorts differed in terms of age distribution, history of chronic pain and 
extent of surgery. Given that these variables all significantly modify patient’s 
reported pain and tolerance of narcotic medications, the adjusted values are 
more likely to reflect the actual effect of the regimen implementation. 
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Interestingly, this reduction in narcotic use did not carry throughout the 
hospitalization course. This may be due to a few reasons. First, the use of 
ketoralac was limited to 48 hours in our protocol. For patients with longer 
hospitalizations, their choice of analgesia would have been limited to 
acetaminophen for mild pain or various narcotic medications for moderate to 
severe pain. Thus, we may not see as much of a benefit from the protocol over 
the hospital course simply because patients had fewer non-narcotic pain relief 
options later in their admission. Future studies assessing narcotic use at various 
post-surgical time points may help pinpoint strategies for improving the 
multimodal analgesia plan to further reduce opioid use during the entire hospital 
course. Second, a patient’s analgesia requirements are not evenly distributed 
throughout their post-operative course. Thus, differences in cumulative opioid 
use may be missed when averaged over the length of hospitalization.  
 Our study findings are in line with previous studies that have shown that 
non-narcotic medications decrease morphine use.24,25 It is difficult to make direct 
comparison, however, given that there is no standard multimodal regimen. 
Previous systematic reviews and meta-analyses have shown the benefit of 
adding single and sometimes two agents whereas our protocol describes a more 
comprehensive order set and strategy.24,25 A drawback of this strategy is that it is 
more difficult to parse out the contributions of the individual pain medications in 
terms of opioid use reduction.  Review of a large database of orthopedic patients 
found that NSAIDs and COX-2 inhibitors seemed to be the most effective 
modalities used 26. An important concept that underpins multimodal non-opioid 
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analgesia is the concept of preventative analgesia. The goal of administering 
alternative modes of analgesia is to modify the transmission and processing of 
painful stimuli to decrease the central nervous system’s experience of pain.32,33 
Our study was not designed to assess the individual components of the 
multimodal analgesia plan and thus the incremental benefit of adding each 
additional medication utilized remains unclear.  
 While there was a significant reduction in the amount of opioids used in 
the first 24 hours, it is important to note that opioid consumption even after 
protocol implementation remained high. Our reported post-operative opioid 
usage is higher than reported in other Otolaryngology studies. 28,34 This may be 
due to our inclusion of narcotic medications given immediately in the post 
anesthesia care unit (PACU) and surgical salvage patients who are more likely to 
have high baseline chronic opioid use related to their disease. Nearly a third of 
our patients reported chronic pain before surgery and a fifth had baseline 
narcotic use. Nevertheless, the CDC advises caution with opioid dosages of 
more than 50 MME/day and avoiding 90 MME/day whenever possible. 35 The 
CDC recommendations are specific for opioid prescriptions for chronic pain but it 
does raise the question of how much opioid is too much for episodic use. Given 
that some patients are opioid naïve, the post-surgical cohort ought to be more 
sensitive to both the analgesic and the adverse effects of narcotic medications. 
We do not know if there is an opioid dose threshold below which the risk of 
developing addiction is significantly decreased. In this study 16/220 (7.3%) 
patients did not receive any narcotic medications post-operatively. In the study by 
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Oltman et al, 39/222 (17.6%) patients were managed post-surgically without any 
narcotic medications. The goal of opioid-sparing analgesia should not only be to 
decrease opioid use but to better understand clinical scenarios in which post-
operative narcotic use can be avoided altogether.  
 The side effects of opioid medications have been well documented. 
However, it is important to keep in mind that medications utilized in the 
multimodal analgesia protocol also have potential adverse effects. The main 
concern in using NSAIDs after surgery, especially in the H&N region, is the risk 
of post-operative bleeding. We did not find any increase in hematoma or bleeding 
requiring reoperation after protocol implementation. A meta-analysis of 27 
studies of randomized control trials did not find any increase in postoperative 
bleeding with ketorolac 36. Though other studies have also shown no significant 
difference in bleeding rates after H&N procedures or tonsillectomies with 
NSAIDs, 37,38there continues to be concern that NSAID administration may 
increase the severity of hemorrhage when it does occur or the ooziness of 
surgical wounds 39. Meticulous control of hemostasis and diligent monitoring of 
patients’ post-operative course will continue to be important in order to ensure 
that routine use of NSAIDs in post-operative care won’t lead to deleterious 
outcomes. Gamma-amiobutyric acid (GABA) agonists, such as gabapentin and 
pregabalin, have been used in numerous surgical populations safely.34,40 Side 
effects include dizziness, drowsiness, nausea, extremity swelling and 
constipation and appear to be dose dependent. 41,42 GABA-agonists are 
considered to have low addictive potential but there are some reports of 
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individuals self-administering extremely high doses of these medications, often in 
conjunction with opioids or other narcotic medication.43,44 Finally, numerous 
studies have shown that being prescribed numerous medications – 
polypharmacy – can independently increase a patient’s risk of adverse health 
outcomes, particularly in the elderly.45,46 We must be cautious that by using 
multiple non-narcotic medications to decrease use of opioids we do not simply 
substitute one problem for another.   
 In this study, we found that a decrease in narcotic consumption in the first 
24 hours after surgery was not associated with any change in pain scores. This 
may indicate that the level of pain control did not change despite less opioid use. 
However, it may also reflect the fact that pain scores and narcotic dose measure 
different outcomes. On multivariate analysis, we find that older patients and 
males reported lower pain scores. We also see that the severity of post-operative 
pain anticipated by patients has the strongest association with pain scores 
reported in the first 24 hours. While we see that older patients also utilized less 
narcotic medications, multivariate analysis of 24h opioid use showed no 
significant association with sex or anticipated pain levels. Rather, pre-operative 
narcotic use and extent of surgery were significantly correlated with narcotic use. 
Post-surgical narcotic use is partly dictated by physician orders and may also 
reflect surgeon’s expectations of how much pain patients will experience after 
surgery. Additional studies are needed to parse out this distinction so as to target 
future efforts to decrease unnecessary opioid use in the post-surgical setting.   
	   19	  
 There are numerous limitations of this study that have not already been 
mentioned. First, the study results are limited to the inpatient course. While 
decreasing narcotic use in the hospital is of value, it will be important to 
understand the long-term ramifications of a multimodal analgesia protocol. 
Second, pain score and MME were measured in the first 24 hours after surgery 
because they were available for all patients. However, the immediate post-
operative period may not be the optimal time to assess for changes resulting 
from multimodal analgesia. Immediately after surgery, patient’s pain experience 
may still be altered by medications given intraoperatively. A previous study 
looking at pain assessments after H&N surgery found that median pain score 
was highest on postoperative day 6.47 Opioid usage, similarly, may vary 
throughout the hospital course. This variability in the postoperative course 
experience of pain limits our ability to compare our findings to other similar 
studies. Finally, this study included a wide range of surgical procedures spanning 
from relatively simple neck mass excisions to complex multi-component ablative 
and reconstructive procedures. Given the difficulties in predicting the exact 
degree of pain associated with each surgical procedure, the division of surgical 
procedures into “minor” and “major” ones may be somewhat arbitrary. The 
addition of non-narcotic medications may be of substantial benefit in one subset 
and simply unnecessary in another. The goal of grouping all H&N patients under 
a single multimodal analgesia protocol was to show its feasibility and assess its 
general effects.  
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 Our findings suggest that multimodal analgesia may be helpful in 
decreasing opioid use after H&N surgery. However, there is a great deal 
regarding the optimal role of multimodal analgesia that needs further 
investigation. Additional studies are needed to assess the safety and cost 
effectiveness of multimodal analgesia strategies. Future studies are also needed 
to assess whether such strategies are sufficient to decrease the long-term use of 
chronic opioid use.  
 
CONCLUSIONS 
 A multimodal analgesia protocol was successfully initiated at our institution 
for use after H&N surgical procedures. Implementation of the protocol was 
associated in a decrease in narcotic use immediately after surgery but did not 
alter patients’ pain scores. Patient’s experience of pain is largely influenced by 
their age and anticipation of pain. Although these variables also influence opioid 
doses, the quantity of narcotic medications used after surgery is also associated 
with baseline narcotic use and the extent of surgery. The experience at our 
institution suggests that multimodal analgesia protocols may be a valuable tool 
for post-operative pain control amid the current opioid epidemic. However, the 
optimal combination of these medications, their long-term effectiveness and 
safety, and the cost effectiveness of these strategies compared to existing 
analgesia strategies merit further research and evaluation.  
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TABLE 1: Characteristics of Patients pre and post pain protocol implementation 
 
 
SD: Standard deviation. RTOR: Return to Operating Room. BMI: Body Mass 
Index 
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TABLE 2: Postoperative Non-Narcotic Pain Medication Utilization 
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TABLE 3: Bivariate Analysis of Patient and Surgical Characteristics and Opioid 
Use in First 24 Hours After Surgery and Averaged Throughout Hospitalization  
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TABLE 4: Bivariate Analysis of Patient and Surgical Characteristics and Average 
Pain Scores in First 24 Hours After Surgery and on Day of Discharge.  
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TABLE 5: Pain Scores and Opioid Usage Pre and Post Protocol Implementation 
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APPENDIX I 
LIMITED SYSTEMATIC REVIEW 
 A limited systematic reviewed was performed to identify studies that 
assess effect of multimodal analgesia on opioid use after head and neck surgery. 
A PubMed search was performed using the search terms Otolaryngology 
multimodal pain management, head and neck post-surgical pain management, 
neck surgery multimodal analgesia, opioid sparing head and neck surgery, 
Otolaryngology narcotic requirement and Otolaryngology opioid use. The search 
was filtered to human studies published in English.  
 A total of 228 articles were identified through PubMed search (Figure 1). 
Sixty-five full text articles were reviewed. The majority of articles were excluded 
as they focused on pediatric tonsillectomy patients or endoscopic sinus surgery 
procedures. Studies were also excluded if they did not specifically assess a non-
narcotic analgesic medication or did not report opioid dosages. Three studies 
assessed a non-narcotic analgesic medication and its affect on opioid doses in 
this surgical population but only assessed a single medication. One article met 
inclusion criteria of studying multimodal analgesia effects on opioid use after 
head and neck surgical procedures.  
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Figure 1: PRISMA Flow Diagram of Limited Systematic Review of Multimodal 
Analgesia for Post-surgical Pain Control of Head and Neck Surgery Patients.   
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APPENDIX II 
PRE-OPERATIVE PATIENT SURVEY 
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APPENDIX III 
POST-OPERATIVE PATIENT SURVEY 
 
 
 
